At the news
? NEUTRALIMPACT 1/10 144 filed Nov 16, 2026 at 10:22 ET
Director Sangeeta Bhatia filed a Form 144 notice of intent to sell 271 shares of Vertex Pharmaceuticals, valued at approximately $148,470. The shares were acquired via restricted stock vesting on May 1, 2025, as compensation. The sale is de minimis relative to the company's $137.6B market cap and the insider's total holdings, and is routine for director compensation.
- Filer: Sangeeta Bhatia, Director of Vertex Pharmaceuticals
- Shares to be sold: 271 shares of common stock
- Approximate dollar value: $148,470.06
- Shares acquired on May 1, 2025 via restricted stock vesting (compensation)
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access